Categories AlphaGraphs, Earnings, LATEST, Retail

Macy’s stock drops despite earnings beat

Macy’s Inc. (M) beat analyst expectations on sales and earnings numbers for the second quarter of 2018, despite sales seeing a slight decline from the prior-year period. The company also raised its earnings outlook for the full year of 2018. The stock, however, dropped 5% in premarket trade.

The retailer reported net sales of $5.57 billion for Q2 2018, down 1.1% from the same period last year. Comparable sales on an owned basis were flat – while, on an owned plus licensed basis, they were up 0.5%. Comp sales on an owned plus licensed basis beat market estimates.

Net income attributable to shareholders was $166 million or $0.53 per share compared to $111 million or $0.36 per share last year. Adjusted net income was $185 million or $0.59 per share.

Macy's second quarter 2018 earnings
Macy’s Q2 2018 Earnings Infographic

Macy’s revised its guidance for full-year 2018. The company now expects adjusted diluted EPS to be $3.95 to $4.15. Total sales growth is expected to range from flat to a 0.7% increase. Comparable sales on an owned plus licensed basis are expected to increase between 2.1% to 2.5%. Comp sales on an owned basis are expected to be 20 basis points to 30 basis points below comp sales on an owned plus licensed basis.

Macy’s saw strength across all its operating divisions – Macy’s, Bloomingdale’s and Bluemercury. The company’s brick & mortar business along with its online business performed well during the quarter, helped by the strategic initiatives it has been undertaking over the past couple of months. Despite this, sales are still seeing pressure from shifts in consumer trends and Amazon’s strong e-commerce presence.

Related: Macy’s Q2 2018 Earnings Transcript

Related: Earnings Preview: Will Macy’s continue its mojo?

Related: Macy’s Q1 2018 Earnings Infographic

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top